Who We Are
Investor RelationsNews

Indegene helps top 20 pharma company ‘shift right’ on the material review maturity curve ​

The Customer

One of the world’s leading biopharmaceutical companies with 6 lines of business. Operates 100+ brands across 20+ markets and generates 10,000+ assets annually, working with 7 major agency partners


  • 1.5X growth in assets, especially in digital formats, for a span of 2 years. The average time to market had increased by 40% for the same period​

    Nonstandard process and varying degree of material review maturity across brands and affiliates​

    Sparse tracking of metrics and limited visibility into process curtailing ability to manage agency performance and optimize MLR operations​

The Solution

Extensive as is process study-through stakeholder interviews and analysis of review platform data; identified bottlenecks, gaps, and sources of compliance risks

Tier-based review approach based on content risk profiles, avoiding every asset going through the same level of review

AI/ML-assisted reviews to enhance reviewer productivity, introducing pre-and post-MLR stages to reduce the burden of non-core activity on reviewers

Comprehensive KPI framework for analytics based governance and implemented phased training and change management for material review stakeholders


Our client was able to streamline material review process, improve agency performance (first time rights, adherence to SLAs, and submission guidelines), and harmonize global to affiliate process flow


Improvement in material review cycle time


Reduction in cost/asset


Person-hours saved in process and tech